BRISTOL MYERS SQUIBB
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France
Recruiting
- Conditions
- Esophageal Adenocarcinoma (EAC)Gastro-esophageal Junction AdenocarcinomaEsophageal Squamous Cell Carcinoma (ESCC)Gastric Adenocarcinoma
- Interventions
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 500
- Registration Number
- NCT06504615
- Locations
- 🇫🇷
KAPPA SANTE Institution, Paris, France
🇫🇷Kappa Santé, Paris, France
Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer
Active, not recruiting
- Conditions
- Esophageal CancerGastroesophageal Junction Cancer
- Interventions
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 115
- Registration Number
- NCT06499298
- Locations
- 🇨🇳
Local Institution - 0001, Shanghai, China
A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants
Phase 1
Recruiting
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 32
- Registration Number
- NCT06493409
- Locations
- 🇺🇸
Fortrea - Daytona Beach, Daytona Beach, Florida, United States
A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 400
- Registration Number
- NCT06487156
- Locations
- 🇮🇹
Istituto Nazionale Tumori - IRCCS Fondazione G.Pascale, Napoli, Italy
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
Phase 1
Recruiting
- Conditions
- Healthy VolunteersAnemia, Sickle Cell
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 184
- Registration Number
- NCT06481306
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Local Institution - 0032, Pittsburgh, Pennsylvania, United States
🇺🇸Local Institution - 0021, La Jolla, California, United States
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of Single Doses of BMS-986435 (MYK-224) in Healthy Chinese Participants
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 20
- Registration Number
- NCT06476821
- Locations
- 🇨🇳
Local Institution - 0001, Xuhui District, Shanghai, China
A Study Evaluating Deucravacitinib Concentrations in the Breast Milk and Plasma of Healthy Lactating Female Participants
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 8
- Registration Number
- NCT06476834
- Locations
- 🇺🇸
Local Institution - 0001, Las Vegas, Nevada, United States
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Phase 1
Recruiting
- Conditions
- High-grade Serous Ovarian Carcinoma (HGSOC)Uterine Serous Carcinoma (USC)Non-small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 240
- Registration Number
- NCT06476808
- Locations
- 🇨🇦
BC Cancer Vancouver, Vancouver, British Columbia, Canada
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer
Active, not recruiting
- Conditions
- Gastric CancerGastroesophageal Junction Cancer
- Interventions
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 260
- Registration Number
- NCT06452329
- Locations
- 🇨🇳
Local Institution - 0001, Wuhan, Hubei, China
🇨🇳Tianjin Happy Life Technology Co., Ltd, Shanghai, China
Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments
Not yet recruiting
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Drug: Approved Non-small Cell Lung Cancer (NSCLC) therapies
- First Posted Date
- 2024-06-07
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 55
- Registration Number
- NCT06448793
- Locations
- 🇬🇧
Evidera, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath